{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T03:32:46Z","timestamp":1648870366828},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          COVID-19 bei Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen\u2002Eine erh\u00f6hte Entz\u00fcndungsaktivit\u00e4t bei Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen ist mit schwereren COVID-19-Verl\u00e4ufen assoziiert. Der Einsatz von Glukokortikoiden (mehr als 5\u200amg Prednisolon\/Tag) kann einen schwereren Verlauf von COVID-19 beg\u00fcnstigen. Glukokortikoide von &gt;\u200a10\u200amg \u00fcber einen l\u00e4ngeren Zeitraum m\u00fcssen angesichts zahlreicher steroidsparender Alternativen sehr gut begr\u00fcndet sein.*\n        <\/jats:p><jats:p>\n          COVID-19 und Immunmodulation\u2002Bereits fr\u00fche Fallberichte deuteten auf einen negativen Einfluss von Rituximab auf den Verlauf von COVID-19 hin. Mittlerweile konnten in mehreren Arbeiten h\u00f6here Raten von Hospitalisierungen und COVID-19-assoziiertem Tod nachgewiesen werden. Ob ein vergleichbarer Effekt auch unter der Therapie mit Januskinase-Inhibitoren bei Patienten mit rheumatoider Arthritis besteht, wird derzeit untersucht.<\/jats:p><jats:p>\n          COVID-19-Impfungen\u2002Alle in Deutschland zur Verf\u00fcgung stehenden Impfstoffe gegen COVID-19 weisen bisher ein sehr gutes Sicherheitsprofil sowie kein relevant erh\u00f6htes Risiko f\u00fcr Krankheitssch\u00fcbe auf. Es wird keine generelle Pausierung oder Reduktion der Immunmodulation zum Erzielen einer besseren Impfantwort empfohlen. Eine Ausnahme stellt die Therapie mit Rituximab dar.<\/jats:p>","DOI":"10.1055\/a-1616-8742","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:14:51Z","timestamp":1637972091000},"page":"1564-1568","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 und rheumatische Erkrankungen \u2013 bisherige\u00a0Erkenntnisse der Pandemie"],"prefix":"10.1055","volume":"146","author":[{"given":"Rebecca","family":"Hasseli","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Rheumatologie und klinische Immunologie. Justus-Liebig-Universit\u00e4t Gie\u00dfen, Campus Kerckhoff Bad\u00a0Nauheim"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf M\u00fcller","family":"Ladner","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Rheumatologie und klinische Immunologie. Justus-Liebig-Universit\u00e4t Gie\u00dfen, Campus Kerckhoff Bad\u00a0Nauheim"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Z Wu","year":"2020","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"A Parasher","year":"2021","journal-title":"Postgrad Med J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/postgradmedj-2020-137785","article-title":"Hydroxychloroquine and covid-19","volume":"96","author":"N Sinha","year":"2020","journal-title":"Postgrad Med J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e592","DOI":"10.1016\/S2665-9913(20)30313-1","article-title":"COVACTA trial raises questions about tocilizumab\u02bcs benefit in COVID-19","volume":"2","author":"B Furlow","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"X Xu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","volume":"384","author":"C Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"A C Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","author":"V C Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","author":"A C Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e001332","DOI":"10.1136\/rmdopen-2020-001332","article-title":"National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD","volume":"6","author":"R Hasseli","year":"2020","journal-title":"RMD Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e001464","DOI":"10.1136\/rmdopen-2020-001464","article-title":"Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"7","author":"R Hasseli","year":"2021","journal-title":"RMD Open"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2665-9913(20)30095-3","article-title":"Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries","volume":"2","author":"M A Gianfrancesco","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"A Strangfeld","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00393-020-00851-x","article-title":"Handlungsempfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie e.\u200aV. f\u00fcr die Betreuung von Patienten mit entz\u00fcndlich rheumatischen Erkrankungen im Rahmen der SARS-CoV-2\/COVID-19-Pandemie \u2013 Update Juli 2020. [Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2\/COVID-19 pandemic \u2013 Update July 2020]","volume":"79","author":"H Schulze-Koops","year":"2020","journal-title":"Z\u00a0Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00393-021-01056-6","article-title":"Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie f\u00fcr die Betreuung von Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV-2\/COVID-19-Pandemie einschlie\u00dflich Empfehlungen zur COVID-19-Impfung. [Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2\/COVID-19 pandemic, including recommendations for COVID-19 vaccination.]","volume":"80","author":"C Specker","year":"2021","journal-title":"Z\u00a0Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"keab230","DOI":"10.1093\/rheumatology\/keab230","article-title":"The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication \u2013 a cross sectional study over 3 months in Germany","author":"R Hasseli","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1136\/annrheumdis-2020-218075","article-title":"Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab","volume":"80","author":"H Schulze-Koops","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00393-017-0393-2","article-title":"S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. [S1 guidelines on diagnostics and treatment of ANCA-associated vasculitis]","volume":"76","author":"J H Schirmer","year":"2017","journal-title":"Z Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","article-title":"S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs]","volume":"77","author":"C Fiehn","year":"2018","journal-title":"Z Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"J A Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e001814","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"7","author":"S E Sattui","year":"2021","journal-title":"RMD Open"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1616-8742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:15:53Z","timestamp":1637972153000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1616-8742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":21,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1616-8742","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}